- Open
- 5.50
- High
- 6.00
- Low
- 5.69
- Close
- 5.69
- Change
- +0.10 (1.96%)
- Volume
- 36,415
| 29 Jul 2026 | 07:00:03 | Trading update for the year ended 30 June 2026 |
| 28 Jul 2026 | 07:00:06 | Appointment of Executive Chairman |
| 30 Jun 2026 | 07:00:06 | Vesting of Options under Long-Term Incentive Plan |
| 15 Jun 2026 | 07:00:12 | Long Term Incentive Awards |
| 12 Jun 2026 | 07:00:06 | Allergy Therapeutics to present at EAACI 2026 |
| 4 Jan 2026 | Annual Report and Accounts (to 2025-06-30) | |
| 19 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 7 Mar 2024 | Annual Report and Accounts (to 2023-06-30) |
Allergy Therapeutics plc specializes in the development and commercialization of allergen immunotherapy products aimed at treating allergies by addressing their underlying causes rather than merely alleviating symptoms. The company offers both subcutaneous and sublingual immunotherapy treatments for various allergens, including pollen and peanuts. Its primary markets include Germany, Spain, and Austria, where it generates revenue through the sale of its immunotherapy products. Allergy Therapeutics is focused on advancing its research and development pipeline to enhance patient care in allergy treatment.
| 29 Jul 2026 | 07:00:03 | Trading update for the year ended 30 June 2026 |
| 28 Jul 2026 | 07:00:06 | Appointment of Executive Chairman |
| 30 Jun 2026 | 07:00:06 | Vesting of Options under Long-Term Incentive Plan |
| 15 Jun 2026 | 07:00:12 | Long Term Incentive Awards |
| 12 Jun 2026 | 07:00:06 | Allergy Therapeutics to present at EAACI 2026 |
| 4 Jan 2026 | Annual Report and Accounts (to 2025-06-30) | |
| 19 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 7 Mar 2024 | Annual Report and Accounts (to 2023-06-30) |
Allergy Therapeutics plc specializes in the development and commercialization of allergen immunotherapy products aimed at treating allergies by addressing their underlying causes rather than merely alleviating symptoms. The company offers both subcutaneous and sublingual immunotherapy treatments for various allergens, including pollen and peanuts. Its primary markets include Germany, Spain, and Austria, where it generates revenue through the sale of its immunotherapy products. Allergy Therapeutics is focused on advancing its research and development pipeline to enhance patient care in allergy treatment.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £1.57bn | -0.2% | |
| £303m | -0.1% | |
AGYAllergy Therapeutics PLC | £271m | -0.4% |
| £120m | +0.0% | |
| £44m | — | |
| £22m | +1.5% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £1.57bn | -0.2% | |
| £303m | -0.1% | |
AGYAllergy Therapeutics PLC | £271m | -0.4% |
| £120m | +0.0% | |
| £44m | — | |
| £22m | +1.5% |
